Skip to main content
. 2021 Mar 10;32(4):958–969. doi: 10.1111/jce.14980

Table 2.

Pathology summary

Targeted anatomical location SVC RAA RSPV
Therapy profile Low dose (700 V) High dose (1500 V) High dose (1500 V)
Number of ablated locations (n, total) 6 6 6
Continuous transmurality achieved 6/6 6/6 6/6
Wall thickness in chronic ablation lesion, average (mm) ± of maximum measurements of all slides SD 0.47 ± 0.15 (0.232–0.751) 1.29 ± 0.41 (0.673–2.169) 2.62 ± 1.56c (0.524–6.514)
Wall thickness of adjacent unablated (native) tissue, average (mm) ± SD 0.53 ± 0.23 (0.227–1.017) 1.76 ± 0.92 (0.792–3.668) 2.16 ± 1.32 (0.962–4.652)
Presence of viable myofibers creating cross‐lesional conduits 0/6 0/6 0/6
Additional intralesional observations beyond expected healinga 0/6 0/6 0/6
Ablation is complete based on gross and histological observations (n/n)b 6/6 6/6 6/6
Average temperature rise recorded 1 s post‐delivery 0.70 ± 0.35°C 5.00 ± 1.83°C 4.95 ± 2.52°C

Abbreviations: RAA, right atrial appendage; RSPV, right superior pulmonary vein; SVC, superior vena cava.

a

Expected or typical myocardial remodeling after an ablation treatment 4‐week earlier will result in a bulk of uniform replacement fibrosis extending from the application surface into the myocardial wall. The chronic fibrotic tissue will be devoid of major inflammation, calcification, or significant vascular or epicardial/adventitial changes. In cases of endocardial treatments, minor neointima formation is expected.

b

An ablation is morphologically denoted as “complete” when it is circumferentially transmural along an orifice or around a tubular structure.

c

All six RSPV ablations extended into right atrial tissues, extending the lesion depths into this adjoining atrial myocardium.